Scinai Immunotherapeutics
Formerly BiondVax Pharmaceuticals
Innovative Immunotherapeutic Treatments
Startup Public Health Tech & Life Sciences Est. 2003
🌐 WebsiteLinkedInTwitterCareers
Total Raised
$63.94M
Public
Last Round
$246K
12 rounds
Investors
1
1 public
Team
4
11-50 employees
Confidence
101/100
News
114
articles
Patents
1
About
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business Model
B2B2CB2B
Tags
immunotherapyautoimmune-diseasespharmaceuticalsviral-diseasesbiotechnologytherapeuticsinfectious-diseasedrug-discoverytreatmentsdrug-deliverybiopharmaceuticalvaccinespatientsnanotechnology
Funding & Events
Sep 2023
PIPE $1.33M
Undisclosed Investor(s)
Sep 2017
Exit Undisclosed
Sep 2014
Non-equity $1.3M
Office of the Chief Scientist
Oct 2025
Non-equity $246K
Israel Innovation Authority
May 2015
Exit Undisclosed
Jun 2025
Exit Undisclosed
Jul 2019
PIPE $16.7M
Jan 2017
PIPE $2.85M
Undisclosed Investor(s)
Jan 2017
Exit Undisclosed
Jan 2008
Exit Undisclosed
Dec 2022
Exit Undisclosed
Dec 2021
Exit Undisclosed
Aug 2017
Non-equity $750K
Israel Innovation Authority
Apr 2019
Non-equity $4.46M
European Investment Bank (EIB)
News (114)
Oct 6, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company with a growing boutique contract...
Investment
Sep 2, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and...
InvestmentPartnersProduct Stage
Jun 12, 2025 · finance.yahoo.com
growth-positive
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
InvestmentPartnersCustomers
Jun 12, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering...
InvestmentPartnersCustomers
Jun 5, 2025 · finance.yahoo.com
growth-positive
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
Acquisition
Jun 5, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological...
Acquisition
May 30, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and...
Product StageInvestment
May 30, 2025 · finance.yahoo.com
growth-positive
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
Product StageInvestment
May 7, 2025 · finance.yahoo.com
growth-positive
Scinai Announces Annual Financial Results for 2024
Product StageCustomers
May 1, 2025 · finance.yahoo.com
growth-positive
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
AcquisitionProduct Stage
Mar 27, 2025 · www.prnewswire.com
growth-positive
Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating...
Product StageAcquisitionInvestment
Mar 27, 2025 · finance.yahoo.com
growth-positive
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
Product StageAcquisition
Mar 17, 2025 · finance.yahoo.com
growth-positive
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
PartnersInvestment
Mar 17, 2025 · www.prnewswire.com
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological...
Mar 5, 2025 · finance.yahoo.com
growth-positive
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT
Investment
Jan 6, 2025 · finance.yahoo.com
growth-positive
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
PartnersInvestment
Dec 16, 2024 · finance.yahoo.com
growth-positive
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
PartnersExpand
Dec 16, 2024 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
CustomersPartners
Dec 5, 2024 · finance.yahoo.com
growth-positive
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Management Changes
Nov 29, 2024 · finance.yahoo.com
growth-negative
There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability
+ 94 more articles
Details
Product Stage
Clinical Trial
Employees
11-50
Exact Count
32
District
Jerusalem District
Founded
2003
Registrar
513436105
Crunchbase
biondvax
Locations
Jerusalem BioPark, Hadassah Ein Kerem Campus
Links
Website
www.scinai.com/
LinkedIn
Profile
Twitter
Profile
Facebook
Page
Careers
Open positions
Admin
Last Update
Oct 15, 2025
Verified by
Yanina Wainscheinker
Claimed
Yes
Missing
markets
Team (4)
Amir Reichman
CEO
Elad Mark
COO
Tamar Ben-Yedidia, PhD
CSO
Joshua E. Phillipson
Business Development & Marketing Manager
Internal
Created by
Jenny Sotnik-Talisman (genys30@yahoo.com)
Created
2014-09-10T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Status
Acquired by Pincell srl on Jun, 2025
Finder · Scinai Immunotherapeutics · 2026